Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis

Next Previous
Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucravacitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 12 Aug 2022 Results assessing efficacy of deucravacitinib over 52 weeks in the POETYK PSO-1 and POETYK PSO-2 trials published in the American Journal of Clinical Dermatology
  • 13 Jan 2022 Results of post hoc analysis evaluating the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assessing the relationship between these outcomes in adults with psoriasis published in the Dermatology and Therapy
  • 15 Jun 2019 Results assessing influence of baseline demographics and disease charecteristics on efficacy of BMS-986165 presented at the 20th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top